Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma

American Journal of Pathology

Volumn 163, Issue 2, 2003, Pages 683-690

  Behrmann, Iris ^a   Wallner, Susanne ^b   Komyod, Waraporn ^a   Heinrich, Peter C ^a   Schuierer, Marion ^b   Buettner, Reinhard ^c   Bosserhoff, Anja Katrin ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; BETA ACTIN; DNA; INTERFERON; MESSENGER RNA; PHOSPHORYLASE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME DELETION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 0042846001     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63695-4     Document Type: Article

References (22)

1. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, David M: Arginine methylation of STAT1 modulates IFNα/β-induced transcription. Cell 2001, 104:731-741
2. Christopher SA, Diegelman P, Porter CW, Kruger WD: Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002, 62:6639-6644
3. Garcia-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R: Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002, 8:782-787
4. Wong YF, Chung TK, Cheung TH, Nobori T, Chang AM: MTAP gene deletion in endometrial cancer. Gynecol Obstet Invest 1998, 45:272-276
5. Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T: The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int J Cancer 1998, 75:51-56
6. Kamatani N, Carson DA: Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. Cancer Res 1980, 40:4178-4182
7. Dobrowolski R, Hein R, Buettner R, Bosserhoff AK: Loss of p14ARF expression in melanoma. Arch Dermatol Res 2002, 293:545-551
8. Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R, Bosserhoff AK: In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid Melanoma Res 1998, 8:211-219
9. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994, 54:5695-5701
10. Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001, 276:24661-24666
11. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 1986, 409:127-147
12. Gunther K, Fleischer A, Buettner R, Bosserhoff AK: Detection of invasion-related chromosomal changes in highly and weakly invasive melanoma cell clones by a modified comparative genomic hybridization approach. Melanoma Res 2001, 11:105-115
13. Chen ZH, Zhang H, Savarese TM: Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the α- and β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 1996, 56:1083-1090
14. Stadler WM, Olopade OI: The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B, and MTAP genes. Urol Res 1996, 24:239-244
15. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 2001, 101:185-189
16. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001, 11:159-168
17. Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA: DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000, 80:1513-1522
18. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ: p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997, 57:2619-2622
19. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380
20. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH: High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2458
21. McClay EF: Adjuvant therapy for patients with high-risk malignant melanoma. Semin Oncol 2002, 29:389-399
22. Lens MB, Dawes M: Interferon α therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002, 20:1818-1825